Show simple item record

dc.creatorMohamed, Hager
dc.creatorGurrola, Theodore
dc.creatorBerman, Rachel
dc.creatorCollins, Mackenzie
dc.creatorSariyer, Ilker K.
dc.creatorNonnemacher, Michael R.
dc.creatorWigdahl, Brian
dc.identifier.citationMohamed H, Gurrola T, Berman R, Collins M, Sariyer IK, Nonnemacher MR and Wigdahl B (2022) Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy. Front. Immunol. 12:816515. doi: 10.3389/fimmu.2021.816515
dc.description.abstractGlobally, human immunodeficiency virus type 1 (HIV-1) infection is a major health burden for which successful therapeutic options are still being investigated. Challenges facing current drugs that are part of the established life-long antiretroviral therapy (ART) include toxicity, development of drug resistant HIV-1 strains, the cost of treatment, and the inability to eradicate the provirus from infected cells. For these reasons, novel anti-HIV-1 therapeutics that can prevent or eliminate disease progression including the onset of the acquired immunodeficiency syndrome (AIDS) are needed. While development of HIV-1 vaccination has also been challenging, recent advancements demonstrate that infection of HIV-1-susceptible cells can be prevented in individuals living with HIV-1, by targeting C-C chemokine receptor type 5 (CCR5). CCR5 serves many functions in the human immune response and is a co-receptor utilized by HIV-1 for entry into immune cells. Therapeutics targeting CCR5 generally involve gene editing techniques including CRISPR, CCR5 blockade using antibodies or antagonists, or combinations of both. Here we review the efficacy of these approaches and discuss the potential of their use in the clinic as novel ART-independent therapies for HIV-1 infection.
dc.format.extent20 pages
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartFrontiers in Immunology, Vol. 12
dc.relation.isreferencedbyFrontiers Media
dc.rightsAttribution CC BY
dc.subjectAntiretroviral drugs
dc.subjectCCR5 monoclonal antibodies
dc.subjectCCR5 small molecule inhibitors
dc.subjectHIV-1 drug resistance
dc.subjectZinc finger nucleases
dc.subjectCombination therapy
dc.titleTargeting CCR5 as a Component of an HIV-1 Therapeutic Strategy
dc.type.genreJournal article
dc.contributor.groupCenter for Neurovirology and Gene Editing (Temple University)
dc.description.departmentMicrobiology, Immunology and Inflammation
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact
dc.description.schoolcollegeLewis Katz School of Medicine
dc.temple.creatorSariyer, Ilker K.

Files in this item

IlkerEtAl-JournalArticle-2022- ...

This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY